Evidence map›Paper›PMID 20805305›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2010

Endogenous luminal surface adenosine signaling regulates duodenal bicarbonate secretion in rats.

Maggie Ham, Misa Mizumori, Chikako Watanabe, Joon-Ho Wang, Takuya Inoue, Takanari Nakano, Paul H Guth, Eli Engel, Jonathan D Kaunitz, Yasutada Akiba

Open access · greenAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Duodenal chemosensing.Current opinion in gastroenterology · 2018
    Review
  6. Xenin Augments Duodenal Anion Secretion via Activation of Afferent Neural Pathways.The Journal of pharmacology and experimental therapeutics · 2017
    Article
  7. Article
  8. Article
  9. Prostaglandin pathways in duodenal chemosensing.Journal of gastroenterology and hepatology · 2014
    Review
  10. Recent advances in gut nutrient chemosensing.Current medicinal chemistry · 2012
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Maggie HamDepartment of Medicine, School of Medicine, University of California, Los Angeles, California, USA.
Misa Mizumori
Chikako Watanabe
Joon-Ho Wang
Takuya Inoue
Takanari Nakano
Paul H Guth
Eli Engel
Jonathan D Kaunitz
Yasutada Akiba
University of California, Los Angeles · US

Funding

Duodenal Muscosal Defense MechanismsR01DK054221 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KAUNITZ, JONATHAN D. · 1999 to 2016
$4.4M
BLRD VA I01 BX001245NIDDK NIH HHS P30-DK0413NIDDK NIH HHS R01 DK054221NIDDK NIH HHS R01-DK54221
6 · The paper itself

Abstract

Luminal ATP increases duodenal bicarbonate secretion (DBS) via brush border P2Y receptors. Because ATP is sequentially dephosphorylated to adenosine (ADO) and the brush border highly expresses adenosine deaminase (ADA), we hypothesized that luminal [ADO] regulators and sensors, including P1 receptors, ADA, and nucleoside transporters (NTs) regulate DBS. We measured DBS with pH and CO(2) electrodes, perfusing ADO ± adenosine receptor agonists or antagonists or the cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor CFTR(inh)-172 on DBS. Furthermore, we examined the effect of inhibitors of ADA or NT on DBS. Perfusion of AMP or ADO (0.1 mM) uniformly increased DBS, whereas inosine had no effect. The A(1/2) receptor agonist 5'-(N-ethylcarboxamido)-adenosine (0.1 mM) increased DBS, whereas ADO-augmented DBS was inhibited by the potent A(2B) receptor antagonist N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetamide (MRS1754) (10 μM). Other selective adenosine receptor agonists or antagonists had no effect. The A(2B) receptor was immunolocalized to the brush border membrane of duodenal villi, whereas the A(2A) receptor was immunolocalized primarily to the vascular endothelium. Furthermore, ADO-induced DBS was enhanced by 2'-deoxycoformycin (1 μM) and formycin B (0.1 mM), but not by S-(4-nitrobenzyl)-6-thioinosine (0.1 mM), and it was abolished by CFTR(inh)-172 pretreatment (1 mg/kg i.p). Moreover, ATP (0.1 mM)-induced DBS was partially reduced by (1R,2S,4S,5S)-4-2-iodo-6-(methylamino)-9H-purin-9-yl]-2-(phosphonooxy)bicyclo[3.1.0]hexane-1-methanol dihydrogen phosphate ester tetraammonium salt (MRS2500) or 8-[4-[4-(4-chlorophenzyl)piperazide-1-sulfonyl)phenyl]]-1-propylxanthine (PSB603) and abolished by both, suggesting that ATP is sequentially degraded to ADO. Luminal ADO stimulates DBS via A(2B) receptors and CFTR. ATP release, ecto-phosphohydrolases, ADA, and concentrative NT may coordinately regulate luminal surface ADO concentration to modulate ADO-P1 receptor signaling in rat duodenum.

Indexed as

AdenosineAdenosine A2 Receptor AgonistsAdenosine A2 Receptor AntagonistsAdenosine DeaminaseAdenosine MonophosphateAdenosine TriphosphateAnimalsBicarbonatesDuodenumEquilibrative Nucleoside Transport ProteinsIntestinal MucosaMaleMembrane ProteinsMembrane Transport ProteinsPerfusionPurinergic P1 Receptor AgonistsAda protein, ratAdenosineAdenosine A2 Receptor AgonistsAdenosine A2 Receptor AntagonistsAdenosine DeaminaseAdenosine MonophosphateAdenosine TriphosphateBicarbonatescif nucleoside transporterEquilibrative Nucleoside Transport ProteinsMembrane ProteinsMembrane Transport ProteinsPurinergic P1 Receptor AgonistsPurinergic P1 Receptor AntagonistsPurinergic P2Y Receptor AgonistsReceptor, Adenosine A2BReceptors, Purinergic P1

Identifiers

PMID20805305
PMCPMC2993549
OpenAlexW2140928216

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.